244 related articles for article (PubMed ID: 22035268)
1. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials.
Varkaris A; Corn PG; Gaur S; Dayyani F; Logothetis CJ; Gallick GE
Expert Opin Investig Drugs; 2011 Dec; 20(12):1677-84. PubMed ID: 22035268
[TBL] [Abstract][Full Text] [Related]
2. Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis.
Aldahl J; Mi J; Pineda A; Kim WK; Olson A; Hooker E; He Y; Yu EJ; Le V; Lee DH; Geradts J; Sun Z
J Biol Chem; 2020 Jan; 295(2):631-644. PubMed ID: 31819003
[TBL] [Abstract][Full Text] [Related]
3. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
Dai Y; Siemann DW
Mol Cancer Ther; 2010 Jun; 9(6):1554-61. PubMed ID: 20515943
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R.
Nakashiro K; Hara S; Shinohara Y; Oyasu M; Kawamata H; Shintani S; Hamakawa H; Oyasu R
Am J Pathol; 2004 Aug; 165(2):533-40. PubMed ID: 15277227
[TBL] [Abstract][Full Text] [Related]
6. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
[TBL] [Abstract][Full Text] [Related]
7. Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells.
Tate A; Isotani S; Bradley MJ; Sikes RA; Davis R; Chung LW; Edlund M
BMC Cancer; 2006 Jul; 6():197. PubMed ID: 16869958
[TBL] [Abstract][Full Text] [Related]
8. Targeting the HGF/Met signaling pathway in cancer therapy.
Cecchi F; Rabe DC; Bottaro DP
Expert Opin Ther Targets; 2012 Jun; 16(6):553-72. PubMed ID: 22530990
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of hepatocyte growth factor and its receptor, c-Met, during sex hormone-induced prostatic carcinogenesis in the Noble rat.
Tam NN; Chung SS; Lee DT; Wong YC
Carcinogenesis; 2000 Dec; 21(12):2183-91. PubMed ID: 11133807
[TBL] [Abstract][Full Text] [Related]
10. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.
Dai Y; Siemann DW
BMC Cancer; 2012 May; 12():198. PubMed ID: 22639908
[TBL] [Abstract][Full Text] [Related]
11. c-met proto-oncogene expression in benign and malignant human prostate tissues.
Pisters LL; Troncoso P; Zhau HE; Li W; von Eschenbach AC; Chung LW
J Urol; 1995 Jul; 154(1):293-8. PubMed ID: 7539865
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases.
Whang YM; Jung SP; Kim MK; Chang IH; Park SI
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658428
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
14. The scatter factor signaling pathways as therapeutic associated target in cancer treatment.
Accornero P; Pavone LM; Baratta M
Curr Med Chem; 2010; 17(25):2699-712. PubMed ID: 20586722
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.
Humphrey PA; Zhu X; Zarnegar R; Swanson PE; Ratliff TL; Vollmer RT; Day ML
Am J Pathol; 1995 Aug; 147(2):386-96. PubMed ID: 7639332
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue.
Nakashiro K; Hayashi Y; Oyasu R
Oncol Rep; 2003; 10(5):1149-53. PubMed ID: 12883672
[TBL] [Abstract][Full Text] [Related]
17. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
[TBL] [Abstract][Full Text] [Related]
18. HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.
Hartmann S; Bhola NE; Grandis JR
Clin Cancer Res; 2016 Aug; 22(16):4005-13. PubMed ID: 27370607
[TBL] [Abstract][Full Text] [Related]
19. Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor.
Ghatak S; Hascall VC; Markwald RR; Misra S
J Biol Chem; 2010 Jun; 285(26):19821-32. PubMed ID: 20200161
[TBL] [Abstract][Full Text] [Related]
20. HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers.
Zhang H; Feng Q; Chen WD; Wang YD
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30360560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
